{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:28:11Z","timestamp":1793410091714,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"am","delay-in-days":401,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cca.2023.117326","type":"journal-article","created":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T10:52:30Z","timestamp":1680346350000},"page":"117326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives"],"prefix":"10.1016","volume":"543","author":[{"given":"C\u00e9line","family":"Narjoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahia","family":"Nadour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2023.117326_b0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin. Pharmacokinet."},{"issue":"181","key":"10.1016\/j.cca.2023.117326_b0010","first-page":"3","article-title":"Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency","volume":"2022","author":"Etienne-Grimaldi","year":"1990","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.cca.2023.117326_b0015","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2020","author":"Cervantes","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cca.2023.117326_b0020","unstructured":"EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. Eur Med Agency 2020. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine (accessed November 28, 2022)."},{"key":"10.1016\/j.cca.2023.117326_b0025","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels","volume":"141","author":"Jiang","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cca.2023.117326_b0030","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1111\/bcp.13719","article-title":"Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers","volume":"84","author":"Henricks","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cca.2023.117326_b0035","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/chromsci\/bms085","article-title":"Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma","volume":"50","author":"Coudor\u00e9","year":"2012","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.cca.2023.117326_b0040","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.annonc.2021.02.020","article-title":"Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation","volume":"32","author":"Thomas","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.cca.2023.117326_b0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-021-04354-7","article-title":"Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results","author":"Gaible","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cca.2023.117326_b0050","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"Review on uremic toxins: classification, concentration, and interindividual variability","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2023.117326_b0055","doi-asserted-by":"crossref","unstructured":"S. Callon, M. Brugel, D. Botsen, B. Royer, Slimano F, C. Feliu, et al. Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients, Ther. Adv. Med. Oncol. 2023;15:17588359221148536. https:\/\/doi.org\/10.1177\/17588359221148536.","DOI":"10.1177\/17588359221148536"},{"key":"10.1016\/j.cca.2023.117326_b0060","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","article-title":"Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage","volume":"17","author":"Gamelin","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2023.117326_b0065","unstructured":"Annual Data Report. USRDS. https:\/\/adr.usrds.org\/ (accessed December 9, 2021)."},{"key":"10.1016\/j.cca.2023.117326_b0070","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","article-title":"THE AGING KIDNEY: PHYSIOLOGICAL CHANGES","volume":"17","author":"Weinstein","year":"2010","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.cca.2023.117326_b0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cpt.2608","article-title":"Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study","volume":"112","author":"de With","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cca.2023.117326_b0080","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2023.117326_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2023.117326_b0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cca.2023.117326_b0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/2212697X04666170817123425","article-title":"Upfront dpd deficiency detection to secure 5-fu administration: part 2- application to head-and-neck cancer patients","volume":"4","author":"Launay","year":"2017","journal-title":"Clin Cancer Drugs"},{"key":"10.1016\/j.cca.2023.117326_b0100","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41416-020-0962-z","article-title":"A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency","volume":"123","author":"Pallet","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2023.117326_b0105","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00467-008-0762-9","article-title":"What is new in uremic toxicity?","volume":"23","author":"Vanholder","year":"2008","journal-title":"Pediatr. Nephrol. Berl. Ger."},{"key":"10.1016\/j.cca.2023.117326_b0110","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mds344","article-title":"Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study","volume":"24","author":"Janus","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cca.2023.117326_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000167","article-title":"Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Societ\u00e0 Italiana di Nefrologia (SIN)","volume":"2","author":"Pedrazzoli","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.cca.2023.117326_b0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-020-04158-1","article-title":"Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses","volume":"86","author":"Ozaki","year":"2020","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123001286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123001286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:08:37Z","timestamp":1757862517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898123001286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":24,"alternative-id":["S0009898123001286"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2023.117326","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2023.117326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117326"}}